Why Antidiabetic Vanadium Complexes are Not in the Pipeline of “Big Pharma” Drug Research? A Critical Review

Public academic research sites, private institutions as well as small companies have made substantial contributions to the ongoing development of antidiabetic vanadium compounds. But why is this endeavor not echoed by the globally operating pharmaceutical companies, also known as “Big Pharma”? Intri...

Descripción completa

Detalles Bibliográficos
Autores principales: Scior, Thomas, Guevara-Garcia, Jose Antonio, Do, Quoc-Tuan, Bernard, Philippe, Laufer, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5068500/
https://www.ncbi.nlm.nih.gov/pubmed/26997154
http://dx.doi.org/10.2174/0929867323666160321121138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5068500/
https://www.ncbi.nlm.nih.gov/pubmed/26997154
http://dx.doi.org/10.2174/0929867323666160321121138

Ejemplares similares